Velaprumig Biosimilar Bispecific Antibody (Albumin × CD40L) for Research

Cat No.: GMP-Bios-INN-1449

Anti-ALB therapeutic antibody (Pre-made Velaprumig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Velaprumig (development codes Lu-AG22515/APB-A1) is a humanized bispecific antibody targeting CD40 ligand (CD40LG) and albumin. It is developed by H. Lundbeck A/S for Thyroid Eye Disease in Phase I development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1449-1mg 1mg
GMP-Bios-INN-1449-10mg 10mg
GMP-Bios-INN-1449-100mg 100mg
GMP-Bios-INN-1449-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Velaprumig biosimilar, Bispecific Mixed mAb and scFv, Anti-ALB;CD40LG/CD154 Antibody: Anti-Albumin/ALB/HSA/FDAHT therapeutic antibody
INN Name Velaprumig
Target ALB;CD40LG/CD154
Format Bispecific Mixed mAb and scFv
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Kappa;Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None;1i9r:KM:HL:XY/6w4w:HL
99% SI Structure None;None
95-98% SI Structure None;None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC